Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)

NCT06946225 is registered in ClinicalTrials.gov with Immatics US, Inc. as lead sponsor.

NCT NCT06946225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06946225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)
Lead sponsor
Immatics US, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 25, 2025
Completion date
August 31, 2029
Enrollment
15 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, synovial sarcoma